CFMS - Shares rise as Conformis wins FDA 510(k) approval for knee replacement systems

The FDA has granted Conformis (CFMS) 510(k) approval for its ITotal Identity Cruciate Retaining Knee Replacement System and ITotal Identity Posterior Stabilizing Knee Replacement system.The 510(k) paperwork was received by FDA on Jan. 29 of this year and a decision was rendered on Feb. 17.Conformis says that a key advantage of its knee replacement products is that they have a customized fit and are made specifically for each patient.Conformis shares are up 13.1% to $1.21 in premarket trading.

For further details see:

Shares rise as Conformis wins FDA 510(k) approval for knee replacement systems